Dr. Roberto Andres Novoa, MD

Dr. Novoa practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Novoa's NPI, 1326272089, was assigned on May 11, 2009. Dr. Novoa graduated from Harvard Medical School in 2009. Dr. Novoa's California license number on file is A131200.

Dr. Novoa's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Novoa's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Novoa is also affiliated with Santa Clara Valley Medical Center. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Novoa to 4 more hospitals and 1 medical group, each named with a free account. Dr. Novoa's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Novoa practices, 6 sites in all. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Novoa's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dr. Novoa is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Novoa's licenses on file in 3 states: California, Pennsylvania and Ohio.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, itchy rashes, psoriasis, rash and scalp rash among the conditions Dr. Novoa treats.

CMS data shows 6,354 Medicare services from Dr. Novoa across 22 procedure codes in 2024, for 2,274 Medicare patients. Medicare paid $203,785 for them.

CMS counts 2,274 Medicare patients who saw Dr. Novoa in 2024. The largest group is 65 to 74, with 920 patients. 74% of them have high cholesterol, and 67% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Novoa's median patient age at 54, with 52% women.

In 2024, Dr. Novoa wrote 367 Medicare Part D claims for 99 patients. 91% of them were for generic drugs. CMS names the drug for 239 of them, across 11 drugs with 11 or more claims each, at $11,637 in total drug cost. In 2023, CMS named 176 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Novoa for performance year 2024, reported as part of a group. Dr. Novoa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 196 procedures of removal of skin lesions by Dr. Novoa, more than 79% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 74 papers to Dr. Novoa, published from 2012 to 2025. 2020 was the busiest year, with 13. The most frequent topics are Skin Neoplasms, Immunohistochemistry and Diagnosis, Differential. Dr. Novoa has published most often in J Cutan Pathol. Dr. Novoa's most frequent co-authors are Kerri Elyse Rieger, MD, PhD, Ryanne A. Brown, MD and Justin Meng Ko, MD.

CMS Open Payments shows 4 general payments to Dr. Novoa from 3 drug and device companies from 2017 to 2023. Honoraria make up the largest share, 96% of the total. Stemline Therapeutics Inc. paid the most, $2,400.

Dr. Novoa graduated from Harvard Medical School in 2009.

Dr. Novoa is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.